Search Results - "Siegel, David S."

Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma by Sanchez, Larysa, Wang, Yucai, Siegel, David S, Wang, Michael L

“…Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells. Preclinical studies…”
Get full text

Light Chain Proximal Tubulopathy: Clinical and Pathologic Characteristics in the Modern Treatment Era by Stokes, Michael B, Valeri, Anthony M, Herlitz, Leal, Khan, Abdullah M, Siegel, David S, Markowitz, Glen S, D'Agati, Vivette D

“…Light chain proximal tubulopathy (LCPT) is characterized by cytoplasmic inclusions of monoclonal LC within proximal tubular cells. The significance of…”
Get full text

Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE‐013 by Ribrag, Vincent, Avigan, David E., Green, Damian J., Wise‐Draper, Trisha, Posada, Juan G., Vij, Ravi, Zhu, Ying, Farooqui, Mohammed Z. H., Marinello, Patricia, Siegel, David S.

Get full text

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial by Rajkumar, S Vincent, Prof, Jacobus, Susanna, MS, Callander, Natalie S, MD, Fonseca, Rafael, Prof, Vesole, David H, Prof, Williams, Michael E, Prof, Abonour, Rafat, MD, Siegel, David S, Prof, Katz, Michael, BS, Greipp, Philip R, Prof

“…Summary Background High-dose dexamethasone is a mainstay of therapy for multiple myeloma. We studied whether low-dose dexamethasone in combination with…”
Get full text

Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma by Wang, Michael, Martin, Tom, Bensinger, William, Alsina, Melissa, Siegel, David S., Kavalerchik, Edward, Huang, Mei, Orlowski, Robert Z., Niesvizky, Ruben

“…We previously reported a phase 1b dose-escalation study of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in relapsed or progressive multiple…”
Get full text

Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study by Dimopoulos, Meletios, MD, Siegel, David S, MD, Lonial, Sagar, MD, Qi, Junyuan, MD, Hajek, Roman, MD, Facon, Thierry, MD, Rosinol, Laura, MD, Williams, Catherine, MD, Blacklock, Hilary, MD, Goldschmidt, Hartmut, MD, Hungria, Vania, MD, Spencer, Andrew, MD, Palumbo, Antonio, MD, Graef, Thorsten, MD, Eid, Joseph E, MD, Houp, Jennifer, PharmD, Sun, Linda, PhD, Vuocolo, Scott, PhD, Anderson, Kenneth C, MD

“…Summary Background We aimed to assess efficacy and tolerability of vorinostat in combination with bortezomib for treatment of patients with relapsed or…”
Get full text

Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma by JAKUBOWIAK, Andrzej J, BENSON, Don M, BENSINGER, William, SIEGEL, David S. D, ZIMMERMAN, Todd M, MOHRBACHER, Ann, RICHARDSON, Paul G, AFAR, Daniel E. H, SINGHAL, Anil K, ANDERSON, Kenneth C

“…To evaluate the maximum-tolerated dose (MTD), safety, and efficacy of elotuzumab in combination with bortezomib in patients with relapsed or relapsed and…”
Get full text

Intra-marrow delivery of human interleukin-6-loaded biodegradable microspheres promotes growth of patient-derived multiple myeloma cells in mice by Bariana, Manpreet, Wang, Weiwei, Yin, Zhuozhuo, Sun, Jingyu, Samimi, Shabnam, Anuncio, Shaina A, Cassella, Elena, Xu, Nuo, Hu, Wei, Aptekmann, Ariel, Siegel, David S, Chow, Kar F, Wang, Hongjun, Zakrzewski, Johannes L

“…Not available.Not available…”
Get full text

KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma by Jagannath, Sundar, Lin, Yi, Goldschmidt, Hartmut, Reece, Donna, Nooka, Ajay, Senin, Alicia, Rodriguez-Otero, Paula, Powles, Ray, Matsue, Kosei, Shah, Nina, Anderson, Larry D., Streetly, Matthew, Wilson, Kimberly, Le, Hoa Van, Swern, Arlene S., Agarwal, Amit, Siegel, David S.

“…Patients with relapsed and refractory multiple myeloma (RRMM) who are triple-class exposed (to an immunomodulatory agent, proteasome inhibitor, and anti-CD38…”
Get full text

Elotuzumab for the treatment of multiple myeloma by Wang, Yucai, Sanchez, Larysa, Siegel, David S, Wang, Michael L

“…Elotuzumab is one of the first two monoclonal antibodies that gained FDA approval for the treatment of multiple myeloma (MM). It targets SLAMF7, which is…”
Get full text

Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma by NIESVIZKY, Ruben, MARTIN, Thomas G, BENSINGER, William I, ALSINA, Melissa, SIEGEL, David S, KUNKEL, Lori A, WONG, Alvin F, LEE, Susan, ORLOWSKI, Robert Z, WANG, Michael

“…Carfilzomib, a selective proteasome inhibitor, has shown safety and efficacy in relapsed and/or refractory multiple myeloma. This phase I study in patients…”
Get full text

Ex Vivo Maintenance of Primary Human Multiple Myeloma Cells through the Optimization of the Osteoblastic Niche by Zhang, Wenting, Gu, Yexin, Sun, Qiaoling, Siegel, David S, Tolias, Peter, Yang, Zheng, Lee, Woo Y, Zilberberg, Jenny

“…We previously reported a new approach for culturing difficult-to-preserve primary patient-derived multiple myeloma cells (MMC) using an osteoblast…”
Get full text

Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib by RICHARDSON, Paul G, BRIEMBERG, Hannah, SRKALOVIC, Gordan, ALEXANIAN, Raymond, RAJKUMAR, S. Vincent, LIMENTANI, Steven, ALSINA, Melissa, ORLOWSKI, Robert Z, NAJARIAN, Kevin, ESSELTINE, Dixie, ANDERSON, Kenneth C, AMATO, Anthony A, JAGANNATH, Sundar, WEN, Patrick Y, BARLOGIE, Bart, BERENSON, James, SINGHAL, Seema, SIEGEL, David S, IRWIN, David, SCHUSTER, Michael

“…To determine the frequency, characteristics, and reversibility of peripheral neuropathy from bortezomib treatment of advanced multiple myeloma. Peripheral…”
Get full text

I-OPen: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients by Gill, Sarvarinder K., Unawane, Rashmi, Wang, Shuqi, Ahn, Jaeil, Aleman, Adolfo, Siegel, David S., Vesole, David H., Parmar, Harsh, Phull, Pooja, Biran, Noa

Get full text

Natural killer cells activity against multiple myeloma cells is modulated by osteoblast-induced IL-6 and IL-10 production by Uhl, Christopher, Nyirenda, Themba, Siegel, David S., Lee, Woo Y., Zilberberg, Jenny

“…Natural killer (NK) cells are part of the innate arm of the immune system; as such NK cells can be activated rapidly to target virus-infected cells and tumor…”
Get full text

Reply to "The challenge of cross-trial comparison using limited data" Haematologica. 2014;99(8):e000 by Siegel, David S

Get full text

Patient‐reported outcomes following autologous stem cell transplant for patients with multiple myeloma by Biran, Noa, Zhai, Wanting, Jensen, Roxanne E., Mandelblatt, Jeanne, Kumka, Susan, Unawane, Rashmi, Graves, Kristi D., Vesole, David H, Siegel, David S, Potosky, Arnold L.

“…We evaluated changes in patient‐reported outcomes and cognitive function from pre‐ to 3–6 months post‐treatment among 42 newly diagnosed patients with multiple…”
Get full text

Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma by Siegel, David S, Dimopoulos, Meletios A, Ludwig, Heinz, Facon, Thierry, Goldschmidt, Hartmut, Jakubowiak, Andrzej, San-Miguel, Jesus, Obreja, Mihaela, Blaedel, Julie, Stewart, A Keith

“…Purpose In the ASPIRE study of carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide plus dexamethasone (Rd) in patients with relapsed or…”
Get full text

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma by Siegel, David S., Martin, Thomas, Wang, Michael, Vij, Ravi, Jakubowiak, Andrzej J., Lonial, Sagar, Trudel, Suzanne, Kukreti, Vishal, Bahlis, Nizar, Alsina, Melissa, Chanan-Khan, Asher, Buadi, Francis, Reu, Frederic J., Somlo, George, Zonder, Jeffrey, Song, Kevin, Stewart, A. Keith, Stadtmauer, Edward, Kunkel, Lori, Wear, Sandra, Wong, Alvin F., Orlowski, Robert Z., Jagannath, Sundar

“…Carfilzomib is a next-generation, selective proteasome inhibitor being evaluated for the treatment of relapsed and refractory multiple myeloma. In this…”
Get full text

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study by Richardson, Paul G., Siegel, David S., Vij, Ravi, Hofmeister, Craig C., Baz, Rachid, Jagannath, Sundar, Chen, Christine, Lonial, Sagar, Jakubowiak, Andrzej, Bahlis, Nizar, Song, Kevin, Belch, Andrew, Raje, Noopur, Shustik, Chaim, Lentzsch, Suzanne, Lacy, Martha, Mikhael, Joseph, Matous, Jeffrey, Vesole, David, Chen, Min, Zaki, Mohamed H., Jacques, Christian, Yu, Zhinuan, Anderson, Kenneth C.

“…This multicenter, open-label, randomized phase 2 study assessed the efficacy and safety of pomalidomide (POM) with/without low-dose dexamethasone (LoDEX) in…”
Get full text